Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 162517, 5 pages
http://dx.doi.org/10.1155/2014/162517
Research Article

Serum Omentin-1 as a Disease Activity Marker for Crohn’s Disease

1Department of Gastroenterology, Liaocheng People’s Hospital, Liaocheng 252000, China
2Department of Pathology, Liaocheng Second People’s Hospital, Linqing 252600, China
3Department of Radiology, Binzhou Medical College Hospital, Binzhou 256603, China
4Department of Pharmacy, Liaocheng International Peace Hospital, Liaocheng 252000, China
5Central Laboratory, Liaocheng People’s Hospital, Liaocheng 252000, China
6Department of Pathology, Liaocheng People’s Hospital, Liaocheng 252000, China

Received 24 November 2013; Accepted 31 December 2013; Published 11 February 2014

Academic Editor: Yi-Chia Huang

Copyright © 2014 Yan Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Cougard, A. Desjeux, V. Vitton, K. Baumstarck-Barrau, N. Lesavre, and J. C. Grimaud, “The usefulness of factor XIII levels in Crohn's disease,” Journal of Crohn's and Colitis, vol. 6, no. 6, pp. 660–664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. W. R. Best, J. M. Becktel, and J. W. Singleton, “Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI),” Gastroenterology, vol. 77, no. 4, pp. 843–846, 1979. View at Google Scholar · View at Scopus
  3. C. Lahiff, P. Safaie, A. Awais et al., “The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome,” Alimentary Pharmacology and Therapeutics, vol. 37, no. 8, pp. 786–794, 2013. View at Google Scholar
  4. J. D. Lewis, “The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease,” Gastroenterology, vol. 140, no. 6, pp. 1817–1826, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Schäffler, M. Neumeier, H. Herfarth, A. Fürst, J. Schölmerich, and C. Büchler, “Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue,” Biochimica et Biophysica Acta, vol. 1732, no. 1–3, pp. 96–102, 2005. View at Google Scholar
  6. B. K. Tan, R. Adya, and H. S. Randeva, “Omentin: a novel link between inflammation, diabesity, and cardiovascular disease,” Trends in Cardiovascular Medicine, vol. 20, no. 5, pp. 143–148, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. C. M. de Souza Batista, R. Z. Yang, M. J. Lee et al., “Omentin plasma levels and gene expression are decreased in obesity,” Diabetes, vol. 56, no. 6, pp. 1655–1661, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Mahde, M. Shaker, and Z. Al-Mashhadani, “Study of omentin1 and other adipokines and hormones in PCOS patients,” Oman Medical Journal, vol. 24, pp. 108–118, 2009. View at Google Scholar
  9. P. Yan, D. Liu, M. Long, Y. Ren, J. Pang, and R. Li, “Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus,” Experimental and Clinical Endocrinology and Diabetes, vol. 119, no. 4, pp. 257–263, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. X. Zhong, H. Y. Zhang, H. Tan et al., “Association of serum omentin-1 levels with coronary artery disease,” Acta Pharmacologica Sinica, vol. 32, no. 7, pp. 873–878, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Yamawaki, J. Kuramoto, S. Kameshima, T. Usui, M. Okada, and Y. Hara, “Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells,” Biochemical and Biophysical Research Communications, vol. 408, no. 2, pp. 339–343, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. J. E. Lennard-Jones, “Classification of inflammatory bowel disease,” Scandinavian Journal of Gastroenterology, vol. 24, no. 170, pp. 2–6, 1989. View at Google Scholar · View at Scopus
  13. D. A. Drossman and D. L. Dumitrascu, “Rome III: new standard for functional gastrointestinal disorders,” Journal of Gastrointestinal and Liver Diseases, vol. 15, no. 3, pp. 237–241, 2006. View at Google Scholar · View at Scopus
  14. F. van de Logt and A. S. Day, “S100A12: a noninvasive marker of inflammation in inflammatory bowel disease,” Journal of Digestive Diseases, vol. 14, no. 2, pp. 62–67, 2013. View at Publisher · View at Google Scholar
  15. S. Vermeire, G. van Assche, and P. Rutgeerts, “C-reactive protein as a marker for inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 10, no. 5, pp. 661–665, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Kazama, T. Usui, M. Okada, Y. Hara, and H. Yamawaki, “Omentin plays an anti-inflammatory role through inhibition of TNF-a-induced superoxide production in vascular smooth muscle cells,” European Journal of Pharmacology, vol. 686, no. 1–3, pp. 116–123, 2012. View at Google Scholar
  17. H. Y. Pan, L. Guo, and Q. Li, “Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 88, no. 1, pp. 29–33, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. J. M. Moreno-Navarrete, F. Ortega, A. Castro, M. Sabater, W. Ricart, and J. M. Fernández-Real, “Circulating omentin as a novel biomarker of endothelial dysfunction,” Obesity, vol. 19, no. 8, pp. 1552–1559, 2011. View at Publisher · View at Google Scholar · View at Scopus